Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 9/20 | 0.84 |
| ▸ | SHBG | P04278 | 8/20 | 0.84 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.84 |
| ▸ | SERPINA6 | P08185 | 7/20 | 0.84 |
| ▸ | LMNA | P02545 | 6/20 | 0.84 |
| ▸ | CYP2C19 | P33261 | 5/20 | 0.84 |
| ▸ | HIF1A | Q16665 | 5/20 | 0.84 |
| ▸ | BLM | P54132 | 4/20 | 0.84 |
| ▸ | PMP22 | Q01453 | 4/20 | 0.84 |
| ▸ | TSHR | P16473 | 3/20 | 0.84 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.84 |
| ▸ | NR3C1 | P04150 | 6/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.78 |
| ▸ | MEN1 | O00255 | 2/20 | 0.78 |
| ▸ | MAPT | P10636 | 2/20 | 0.78 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.78 |
| ▸ | MAPK3 | P27361 | 1/20 | 0.78 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.78 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.69 |
| ▸ | PGR | P06401 | 3/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6019058 | 1.00 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| Cortodoxone SCHEMBL17906542 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| Cortodoxone SCHEMBL14360590 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| Cortodoxone SCHEMBL13768127 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| SCHEMBL24358662 | 0.91 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| Cortodoxone SCHEMBL24900239 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| Cortodoxone SCHEMBL42590 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| SCHEMBL9070396 | 0.91 | HSD17B10 (0.84) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| Cortodoxone SCHEMBL13352414 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA | |
| Cortodoxone SCHEMBL1592718 | 0.91 | HSD17B10 (1.00) | HSD17B10SHBGSMN1; SMN2SERPINA6LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-04-28 | — | — | US | disclosed |
| US-9222118-B2 | Screen for inhibitors of filovirus and uses therefor | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2015-12-29 | — | — | US | disclosed |
| US-20110263554-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | WARF - WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-10-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160115518-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | HSD17B10 4017/4885SHBG 4817/4885SMN1; SMN2 2581/4885 |
| US-20110263554-A1 | SCREEN FOR INHIBITORS OF FILOVIRUS AND USES THEREFOR | ZC3HAV1, WASF2, ZC3HAV1L | HSD17B10 4003/4885SHBG 4812/4885SMN1; SMN2 2569/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.